See the definitions below to learn more about lung cancer and understand commonly used words.
See the definitions below to learn more about lung cancer and understand commonly used words.
The ALK gene makes an ALK protein, which may be involved in signaling cell growth. Mutations of the ALK gene have been associated with certain types of cancer, including non-small cell lung cancer, sometimes referred to as NSCLC.
An ALK inhibitor is a type of medicine that is designed to bind to and block the activity of the ALK protein.
ALK (anaplastic lymphoma kinase positive) non-small cell lung cancer is a type of lung cancer involving the mutation of the ALK gene.
Treatment given after surgery to help lower the risk that cancer will come back.
The central nervous system includes the brain and the spinal cord.
An amount you have to pay for healthcare services or medicines. You pay this amount after you pay your deductible. A co-pay is usually a set dollar amount.
The amount of time after starting treatment when a person is alive and no cancer is found.
This is when the cancer is in stages 1, 2, or 3A. In the early stages, the tumor remains in the lung and may not have spread to lymph nodes outside of the lung.
Metastatic lung cancer means that the cancer has started to spread. It’s also called advanced lung cancer, or stage 4.
A cancer that grows from inside your lungs, usually in the cells lining air passages. Not all lung cancers are classified as non-small cell. This is determined by a biopsy of tumor tissue.
When cancer comes back after surgery or treatment.
A tumor that is able to be removed with surgery.
Criteria | ALECENSA dose modification |
---|---|
ALT or AST elevation of >5X ULN with total bilirubin ≤2X ULN | Temporarily withhold until recovery to baseline or to ≤3X ULN, then resume at reduced dose. See dose reduction schedule. |
ALT or AST elevation >3X ULN with total bilirubin elevation >2X ULN in the absence of cholestasis or hemolysis | Permanently discontinue ALECENSA. |
Total bilirubin elevation >3X ULN | Temporarily withhold until recovery to baseline or to ≤1.5X ULN, then resume at reduced dose. See dose reduction schedule. |
Any grade treatment-related ILD/pneumonitis | Permanently discontinue ALECENSA. |
Grade 3 renal impairment | Temporarily withhold until serum creatinine recovers to ≤1.5X ULN, then resume at reduced dose. See dose reduction schedule. |
Grade 4 renal impairment | Permanently discontinue ALECENSA. |
Symptomatic bradycardia | Withhold ALECENSA until recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume ALECENSA at previous dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. If no contributing concomitant medication is identified, or if contributing concomitant medications are not discontinued or dose modified, resume ALECENSA at reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. See dose reduction schedule. |
Bradycardiaa (life-threatening consequences, urgent intervention indicated) | Permanently discontinue ALECENSA if no contributing concomitant medication is identified. If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume ALECENSA at reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm, with frequent monitoring as clinically indicated. Permanently discontinue ALECENSA in case of recurrence. See dose reduction schedule. |
CPK elevation of >5X ULN | Temporarily withhold until recovery to baseline or to ≤2.5X ULN, then resume at same dose. |
CPK elevation >10X ULN or second occurrence of CPK elevation of >5X ULN | Temporarily withhold until recovery to baseline or to ≤2.5X ULN, then resume at reduced dose. See dose reduction schedule. |
Hemolytic anemia | Withhold ALECENSA if hemolytic anemia is suspected. Upon resolution, resume at reduced dose or permanently discontinue. See dose reduction schedule. |
aHeart rate <60 bpm.
ALT=alanine transaminase; AST=aspartate transaminase; bpm=beats per minute; CPK=creatine phosphokinase; ILD=interstitial lung disease; ULN=upper limit of normal.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.